Latest Technology News

Life360 has reported its strongest quarter ever, with record user and subscriber growth in Q4 2025, surpassing full-year revenue and EBITDA guidance. The company forecasts continued momentum with 20% user growth expected in 2026.

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Mayfield Group Holdings has acquired a strategic industrial property adjacent to its BE Switchcraft operations, enabling operational synergies and capacity expansion to support a $30 million contract pipeline.

Visionflex Group’s Q2 FY26 report reveals a 23% rise in annual recurring revenue and improved cash flow, even as overall revenue slips due to lower hardware sales.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Albright Metals has completed a key diamond drilling program at its Golden Pike Project in Canada and initiated antimony drilling at Bond Road, supported by a successful $1.98 million capital raise.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

EPX Limited has successfully raised nearly $295,000 through a Security Purchase Plan, supporting its recent acquisition of Wattwatchers and positioning the company for further expansion.

Objective Corporation Limited has announced an on-market buy-back of up to 9.6 million ordinary shares, representing roughly 10% of its issued capital, set to run from February 2026 to February 2027.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.